ProCE Banner Activity

Recognizing Patterns of Suboptimal Response to First-Line MF Treatment

Slideset

Slides featuring expert perspectives on later line therapeutics for patients with myelofibrosis

Released: December 01, 2023

Share

Faculty

Jean-Jacques Kiladjian

Jean-Jacques Kiladjian, MD, PhD

Professor
Department of Clinical Pharmacology
Université de Paris
Professor
Clinical Investigations Center
Saint-Louis Hospital
Paris, France

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from CTI BioPharma Corp., Geron Corporation, GlaxoSmithKline LLC, and Karyopharm Therapeutics Inc.

CTI BioPharma Corp., a Sobi Company

Geron Corporation

GlaxoSmithKline LLC

Karyopharm Therapeutics Inc.